<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is associated with increased risk of <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although higher BMI and other related factors have been frequently associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, whether the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is associated with the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore assessed the association of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in a subsample of participants of the Women's Health Initiative who had repeated measurements of the components of the syndrome at baseline and during follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>Women with <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline enrollment were excluded </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI) at baseline and in time-dependent analyses </plain></SENT>
<SENT sid="5" pm="."><plain>Among 4862 eligible women, 81 incident cases of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> were identified over a median follow-up of 12 years </plain></SENT>
<SENT sid="6" pm="."><plain>Presence of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> at baseline was associated with increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (HR 2.15, 95% CI 1.30-3.53) and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (HR 2.28, 95% CI 1.31-3.98) </plain></SENT>
<SENT sid="7" pm="."><plain>These associations were largely explained by positive associations of serum <z:chebi fb="105" ids="17234">glucose</z:chebi> and systolic blood pressure with both outcomes </plain></SENT>
<SENT sid="8" pm="."><plain>Time-dependent covariate analyses supported the baseline findings </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that the positive association of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is largely accounted for by serum <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and systolic blood pressure </plain></SENT>
<SENT sid="10" pm="."><plain>The biological mechanism underlying these associations remains to be clarified </plain></SENT>
</text></document>